February 24, 2021
February 24, 2022
Scroll to the Bottom of this Information to Begin this Course
This continuing medical education activity is provided by MedEdicus LLC.
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with dementia-related psychosis (DRP).
The prevalence of dementia is increasing rapidly in the United States. Dementia places a burden on affected individuals and caregivers alike. In particular, symptoms of dementia-related psychosis predict reduced quality of life and future institutionalization. Primary care clinicians are uniquely poised to detect and manage these symptoms and to prevent adverse outcomes. In this activity, updated diagnostic guidelines, expert practice recommendations, and current and emerging treatment strategies will be discussed. The desired results of this activity are for clinicians to recognize psychosis as part of the neurodegenerative process in dementia and treat symptoms effectively while maintaining the safety and quality of life of patients.
After completing this activity, participants will be better able to:
- Discuss strategies for assessment of behavioral and psychological symptoms in persons with dementia
- Integrate assessment of psychotic symptoms into routine care of persons with dementia
- Review best practices for diagnosis of DRP
- Develop evidence-based, safe treatment plans for persons with DRP
- Describe clinical trial data for emerging treatments for DRP
Larry Culpepper, MD, MPH (Chair)
Professor of Family Medicine
Department of Family Medicine
Boston University School of Medicine
Davangere P. Devanand, MBBS, MD
Director, Geriatric Psychiatry
Professor of Psychiatry and Neurology
Columbia University Medical Center
New York, New York
Helen Kales, MD
Professor and Chair
Department of Psychiatry and Behavioral Science
University of California, Davis Health
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education Activity is 1.0 contact hour.
Disclosures of Conflicts of Interest
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Larry Culpepper, MD, MPH
- Consultant: ACADIA Pharmaceuticals, Inc; Allergan; Eisai Inc; Merck & Co., Inc; and Takeda Pharmaceuticals USA, Inc
- Ownership interest: M-3 Information, LLC
Davangere P. Devanand, MBBS, MD
- Consultant: ACADIA Pharmaceuticals, Inc; Genentech, Inc; Green Valley; and Sunovion Pharmaceuticals Inc
Helen Kales, MD, has no relevant commercial relationships to disclose
Rita Khoury, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Instructions for Participation and Credit
To obtain CME/CE credit for this activity, please view the webcast modules, consult referenced sources as necessary, and complete the post-test and evaluation online. To answer the questions, click on your selected choice for each answer, then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.
If you receive a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test twice.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others for any professional use.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Amedco; ACADIA Pharmaceuticals Inc; or FreeCME.
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 221